

ERRATUM

Open Access



Erratum to: Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment

Hiroji Uemura¹, Nobuaki Matsubara², Go Kimura³, Akito Yamaguchi⁴, Dianne Athene Ledesma⁵, Marco DiBonaventura⁶, Ateesha F. Mohamed⁷, Enrique Basurto⁶, Ian McKinnon⁶, Ed Wang⁷, Kristen Concialdi⁶, Aya Narimatsu⁵ and Yasuko Aitoku^{5*}

Erratum

After publication of this work [1] it was noticed that there was a typographical error in the Conclusions. The letter 'a' in 'asymptomatic' should have been removed in the concluding statement as it is inconsistent with the Results and Discussion. The statement in the Conclusions should read: 'Patients who were symptomatic placed significantly more importance on delaying an SSE when expressing medication preferences.'

The original article was corrected. The publisher apologises for this error.

Author details

¹Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan. ²Division of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan. ³Department of Urology, Nippon Medical School, Tokyo, Japan. ⁴Division of Urology, Harasanshin General Hospital, Fukuoka, Japan. ⁵Bayer Yakuhin, Ltd., 2-4-9, Umeda, Kita-ku, Osaka 530-0001, Japan. ⁶Kantar Health, New York, NY, USA. ⁷Bayer Healthcare, Whippany, NJ, USA.

Received: 21 March 2017 Accepted: 21 March 2017

Published online: 28 March 2017

Reference

1. Uemura H, Matsubara N, Kimura G, Yamaguchi A, Ledesma DA, DiBonaventura M, et al. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment. *BMC Urol.* 2016;16:63.

* Correspondence: yasuko.aitoku@bayer.com

⁵Bayer Yakuhin, Ltd., 2-4-9, Umeda, Kita-ku, Osaka 530-0001, Japan